Kisspeptin-10 for Diabetes

Phase-Based Progress Estimates
Massachusetts General Hospital, Boston, MADiabetes+4 MoreKisspeptin-10 - Drug
18 - 40
What conditions do you have?

Study Summary

This trial is studying if kisspeptin can help improve beta-cell responsivity in healthy women.

Eligible Conditions
  • Diabetes
  • Healthy Subjects
  • Pregnancy
  • Female

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: up to 6 months

up to 6 months
Beta-cell responsivity index
Fasting insulin level

Trial Safety

Trial Design

2 Treatment Groups

1 of 2
1 of 2

Experimental Treatment

Non-Treatment Group

25 Total Participants · 2 Treatment Groups

Primary Treatment: Kisspeptin-10 · Has Placebo Group · Phase 1

kisspeptin-10Experimental Group · 2 Interventions: Kisspeptin-10, mixed meal tolerance test · Intervention Types: Drug, Other
PlaceboComparator Group · 1 Intervention: mixed meal tolerance test · Intervention Types: Other
First Studied
Drug Approval Stage
How many patients have taken this drug
Not yet FDA approved

Trial Logistics


Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 6 months

Who is running the clinical trial?

Stephanie B. Seminara, MDLead Sponsor
5 Previous Clinical Trials
533 Total Patients Enrolled
Margaret Lippincott, MDPrincipal InvestigatorMassachusetts General Hospital
2 Previous Clinical Trials
429 Total Patients Enrolled

Eligibility Criteria

Age 18 - 40 · Female Participants · 22 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Your immediate family members do not have a history of diabetes, including during pregnancy.
You cannot currently use illegal drugs.
You have not had a severe reaction to a medication that required emergency medical attention in the past.
You started your period between the ages of 10 and 14.
Women with regular menstrual cycles that occur every 25 to 35 days.
Your body mass index falls within the range of 18.5 to 25.

Frequently Asked Questions

Does this study permit me to become a participant?

"To be considered for inclusion in this trial, female candidates aged between 18 and 40 are sought after. The team is hoping to enroll 25 suitable participants." - Anonymous Online Contributor

Unverified Answer

Are there other experiments that made use of Kisspeptin-10?

"Currently, there is 1 active trial for Kisspeptin-10 in Phase 3. Boston, Massachusetts is hosting multiple studies on the subject and there are other research sites across the US that have joined in this scientific effort." - Anonymous Online Contributor

Unverified Answer

Approximately how many participants are being included in this clinical experiment?

"Correct. Information hosted on verifies that this medical experiment, which was initially shared on September 1st 2019, is actively searching for participants. 25 patients should be enrolled from a single site." - Anonymous Online Contributor

Unverified Answer

Can you detail the safety parameters of Kisspeptin-10 for human use?

"Taking into account the limited data for efficacy and safety, our team at Power assigned Kisspeptin-10 a score of 1 on a scale from one to three." - Anonymous Online Contributor

Unverified Answer

Is enrollment currently open for this medical investigation?

"Affirmative. According to the information located on, this research study is currently enrolling participants at a single site and requires 25 individuals in total. It was first posted back on September 1st 2019, with its most recent update being made July 19th 2022." - Anonymous Online Contributor

Unverified Answer

Is the age criterion for this clinical trial flexible enough to include individuals aged 45 and over?

"As denoted by the trial's inclusion criteria, only those aged between 18 and 40 can register for this clinical study." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.